ROCKAWAY, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced second quarter 2023 financial results and provided an operational update.
Second Quarter 2023 and Recent Highlights
“We recorded record revenue of $3.6 million during the second quarter of 2023, an increase of 65% over the second quarter of 2022,” stated Dan Goldberger, Chief Executive Officer of electroCore. “This is our third consecutive quarter of significant sequential growth fueled by our prescription gammaCore business as well as our new products, Truvaga™, and TAC-STIM.”
Second Quarter 2023 Financial Results
For the quarter ended June 30, 2023, electroCore reported net sales of $3.6 million compared to $2.2 million during the same period of 2022, which represents an approximately 65% increase over the prior year. The increase of $1.4 million is due to an increase in net sales across major U.S. channels including the sale of our prescription gammaCore products in all channels, and revenue from the sales of our nonprescription performance TAC-STIM and Truvaga wellness products.
| (in thousands) | Three months ended June 30, | Three months ended June 30, | % Change | Six months ended June 30, | Six months ended June 30, | % Change | ||||||||||||||||
| Channel | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||
| Rx gammaCore - Department of Veteran Affairs and Department of Defense | $ | 2,081 | $ | 1,190 | 75 | % | $ | 3,786 | $ | 2,430 | 56 | % | ||||||||||
| Rx gammaCore - U.S. Commercial | 441 | 465 | -5 | % | 871 | 741 | 18 | % | ||||||||||||||
| Outside the United States | 424 | 467 | -9 | % | 834 | 772 | 8 | % | ||||||||||||||
| Truvaga | 290 | — | — | 437 | — | — | ||||||||||||||||
| TAC-STIM | 311 | — | — | 399 | — | — | ||||||||||||||||
| Other | 4 | 35 | -89 | % | 4 | 113 | -96 | % | ||||||||||||||
| $ | 3,551 | $ | 2,157 | 65 | % | $ | 6,331 | $ | 4,056 | 56 | % | |||||||||||
Gross profit for the second quarter of 2023 was $3.0 million as compared to $1.8 million for the second quarter of 2022. Gross margin for the second quarter of 2023 was 84% as compared to 83% in the second quarter of 2022.
Total operating expenses in the second quarter of 2023 were approximately $8.0 million as compared to $7.6 million in the second quarter of 2022.
Research and development expense in the second quarter of 2023 was $1.2 million as compared to $1.3 million in the second quarter of 2022. This decrease was due to cost cutting measures offset by targeted investments to support future iterations of our therapy delivery platform, including use of our intellectual property around the delivery of smart phone-integrated and smart phone-connected non-invasive therapies.
Selling, general and administrative expense in the second quarter of 2023 was $6.8 million as compared to $6.3 million in the second quarter of 2022.This increase was due to continued targeted investments in sales and marketing to support our commercial efforts, offset by decreases in insurance and stock-based compensation expense.
GAAP net loss in the second quarter of 2023 was $4.9 million compared to the $5.3 million net loss in the second quarter of 2022.
Adjusted EBITDA net loss in the second quarter of 2023 was $4.5 million as compared to a net loss of $4.9 million in the second quarter of 2022.
The Company defines adjusted EBITDA net loss as GAAP net loss, adjusted to exclude non-operating gains/losses, depreciation and amortization, stock-based compensation expense, severance and other related charges, inventory reserve charges, legal fees associated with stockholders’ litigation, and benefit from income taxes. A reconciliation of GAAP net loss to non-GAAP adjusted EBITDA net loss has been provided in the financial statement tables included in the press release.
Net cash used in operating activities in the quarter ended June 30, 2023, was approximately $3.3 million as compared to $3.2 million in the second quarter of 2022. This increase is primarily due to our investment in product evolution expenditures.
Cash, cash equivalents and restricted cash at June 30, 2023 totaled approximately $8.7 million, as compared to approximately $18.0 million as of December 31, 2022. Subsequent to June 30, 2023, the Company raised net proceeds of approximately $7.5 million through a registered direct offering and concurrent private placements priced “at the market” under Nasdaq rules. With this recent capital raise, the Company had a pro forma cash balance of $16.2 million as of June 30, 2023.
Full Year 2023 Outlook
The Company reiterates its revenue guidance of $14.0 million - $15.0 million for calendar year 2023.
The Company expects cash usage will continue to decrease in coming quarters as revenues increase, the Company reduces R&D expenses and continues to rationalize other operating expenses. Therefore, the Company expects net cash usage to decrease significantly through the year.
Webcast and Conference Call Information
electroCore’s management team will host a conference call today, August 9, 2023, beginning at 4:30 PM EDT.
Investors interested in listening to the conference call, or webcast may dial 877-407-8835 for domestic callers or 201-689-8779 for international callers, using Conference ID: 13739200, or by connecting to the Web: electroCore Earnings Webcast. An archived webcast of the event will be available on the “Investors” section of the company’s website at: www.electrocore.com.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about expectations for revenue for 2023, cash resources through 2024 and beyond, electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; business prospects around its Truvaga wellness and TAC-STIM human performance offerings and other new products and markets, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," and other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, TAC-STIM™, and Truvaga™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, inflation and currency fluctuations, and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall economic and market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.
| electroCore, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except per share data) | ||||||||||||||||
| Three months ended June 30, | Six months ended June 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Net sales | $ | 3,551 | $ | 2,157 | $ | 6,331 | $ | 4,056 | ||||||||
| Cost of goods sold | 585 | 358 | 1,043 | 718 | ||||||||||||
| Gross profit | 2,966 | 1,799 | 5,288 | 3,338 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 1,155 | 1,341 | 2,964 | 2,275 | ||||||||||||
| Selling, general and administrative | 6,799 | 6,278 | 13,509 | 12,464 | ||||||||||||
| Total operating expenses | 7,954 | 7,619 | 16,473 | 14,739 | ||||||||||||
| Loss from operations | (4,988 | ) | (5,820 | ) | (11,185 | ) | (11,401 | ) | ||||||||
| Other (income) expense | ||||||||||||||||
| Interest and other income | (85 | ) | (38 | ) | (204 | ) | (42 | ) | ||||||||
| Other expense | — | — | — | 5 | ||||||||||||
| Total other (income) expense | (85 | ) | (38 | ) | (204 | ) | (37 | ) | ||||||||
| Loss before income taxes | (4,903 | ) | (5,782 | ) | (10,981 | ) | (11,364 | ) | ||||||||
| Benefit from income taxes | — | 445 | 211 | 445 | ||||||||||||
| Net loss | $ | (4,903 | ) | $ | (5,337 | ) | $ | (10,770 | ) | $ | (10,919 | ) | ||||
| Net loss per share of common stock - Basic and Diluted | $ | (1.03 | ) | $ | (1.20 | ) | $ | (2.27 | ) | $ | (2.25 | ) | ||||
| Weighted average common shares outstanding - Basic and Diluted | 4,751 | 4,448 | 4,747 | 4,853 | ||||||||||||
| electroCore, Inc. Condensed Consolidated Balance Sheet Information (unaudited) (in thousands) | ||||||||
| June 30, 2023 | December 31, 2022 | |||||||
| Cash and cash equivalents | $ | 8,442 | $ | 17,712 | ||||
| Restricted cash | $ | 250 | $ | 250 | ||||
| Total assets | $ | 14,222 | $ | 24,756 | ||||
| Current liabilities | $ | 6,575 | $ | 7,045 | ||||
| Total liabilities | $ | 7,158 | $ | 7,670 | ||||
| Total equity | $ | 7,064 | $ | 17,086 | ||||
(Unaudited) Use of Non-GAAP Financial Measure
The Company is presenting adjusted EBITDA net loss because it believes this measure is a useful indicator of its operating performance. electroCore management uses this non-GAAP measure principally as a measure of the company’s core operating performance and believes that this measure is useful to investors because it is frequently used by the financial community, investors, and other interested parties to evaluate companies in the company’s industry. The Company also believes that this measure is useful to its management and investors as a measure of comparative operating performance from period to period. Additionally, the company believes its use of non-GAAP adjusted EBITDA net loss from operations facilitates management’s internal comparisons to historical operating results by factoring out potential differences caused by gains and charges not related to its regular, ongoing business, including, without limitation, non-cash charges and certain large and unpredictable charges such as restructuring expenses.
The Company defines adjusted EBITDA net loss as GAAP net loss, adjusted to exclude non-operating gains/losses, depreciation and amortization, stock-based compensation expense, severance and other related charges, inventory reserve charges, legal fees associated with stockholders’ litigation, and benefit from income taxes.
Following is a reconciliation of GAAP net loss to non-GAAP adjusted EBITDA net loss (in thousands):
| Three months ended June 30, | Six months ended June 30, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| GAAP net loss | $ | (4,903 | ) | $ | (5,337 | ) | $ | (10,770 | ) | $ | (10,919 | ) | |||
| Depreciation and amortization | 322 | 141 | 444 | 247 | |||||||||||
| Stock-based compensation | 183 | 752 | 755 | 1,529 | |||||||||||
| Inventory reserve charge | (10 | ) | — | 65 | — | ||||||||||
| Severance and other related charges | — | — | 332 | — | |||||||||||
| Legal fees associated with stockholders' litigation | 35 | 71 | 35 | 132 | |||||||||||
| Interest and other (income) expense | (85 | ) | (38 | ) | (204 | ) | (37 | ) | |||||||
| Benefit from income taxes | — | (445 | ) | (211 | ) | (445 | ) | ||||||||
| Adjusted EBITDA net loss | $ | (4,458 | ) | $ | (4,856 | ) | $ | (9,554 | ) | $ | (9,493 | ) | |||
The Company’s use of a non-GAAP measure has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of its results as reported under GAAP. Some of these limitations are: the non-GAAP measure does not reflect interest or tax payments that may represent a reduction in cash available; although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and the non-GAAP measure does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements; the non-GAAP measure does not reflect the potentially dilutive impact of equity-based compensation; and the non-GAAP measure does not reflect changes in, or cash requirements for, working capital needs; other companies, including companies in electroCore’s industry, may calculate adjusted EBITDA net loss differently, which reduces its usefulness as a comparative measure.
Because of these and other limitations, you should consider the non-GAAP measure together with other GAAP-based financial performance measures, including various cash flow metrics, net loss, and other GAAP results. A reconciliation of GAAP net loss to non-GAAP adjusted EBITDA net loss has been provided in the preceding financial statements table of this press release.
| Last Trade: | US$9.94 |
| Daily Change: | -0.15 -1.49 |
| Daily Volume: | 89,338 |
| Market Cap: | US$64.110M |
November 13, 2024 September 10, 2024 August 07, 2024 August 01, 2024 June 25, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
